These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 20663044)
21. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Cho YA; Lee W; Choi JS Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082 [TBL] [Abstract][Full Text] [Related]
22. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. Piao YJ; Choi JS J Pharm Pharmacol; 2008 May; 60(5):625-9. PubMed ID: 18416939 [TBL] [Abstract][Full Text] [Related]
23. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells. Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703 [TBL] [Abstract][Full Text] [Related]
24. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. Koolen SL; van Waterschoot RA; van Tellingen O; Schinkel AH; Beijnen JH; Schellens JH; Huitema AD J Clin Pharmacol; 2012 Mar; 52(3):370-80. PubMed ID: 21505085 [TBL] [Abstract][Full Text] [Related]
25. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875 [TBL] [Abstract][Full Text] [Related]
26. Effects of morin on the pharmacokinetics of etoposide in rats. Li X; Yun JK; Choi JS Biopharm Drug Dispos; 2007 Apr; 28(3):151-6. PubMed ID: 17315145 [TBL] [Abstract][Full Text] [Related]
27. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Li X; Choi JS Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149 [TBL] [Abstract][Full Text] [Related]
28. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Kharasch ED; Walker A; Hoffer C; Sheffels P Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460 [TBL] [Abstract][Full Text] [Related]
29. Effects of cysteine on the pharmacokinetics of docetaxel in rats with protein-calorie malnutrition. Choi YH; Yoon I; Kim YG; Lee MG Xenobiotica; 2012 May; 42(5):442-55. PubMed ID: 22067009 [TBL] [Abstract][Full Text] [Related]
30. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Hilli J; Sailas L; Jyrkkiö S; Pyrhönen S; Laine K Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939 [TBL] [Abstract][Full Text] [Related]
31. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Lee CK; Choi JS Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105 [TBL] [Abstract][Full Text] [Related]
32. Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Li C; Kim M; Choi JS Arch Pharm Res; 2010 Sep; 33(9):1395-400. PubMed ID: 20945138 [TBL] [Abstract][Full Text] [Related]
33. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Koolen SL; Beijnen JH; Schellens JH Clin Pharmacol Ther; 2010 Jan; 87(1):126-9. PubMed ID: 19924122 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693 [TBL] [Abstract][Full Text] [Related]
35. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Hong SP; Chang KS; Koh YY; Choi DH; Choi JS Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809 [TBL] [Abstract][Full Text] [Related]
36. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Li C; Lee MY; Choi JS Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320 [TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. Hirunpanich V; Murakoso K; Sato H Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981 [TBL] [Abstract][Full Text] [Related]
38. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Engels FK; Loos WJ; Mathot RA; van Schaik RH; Verweij J Cancer Chemother Pharmacol; 2007 Sep; 60(4):569-79. PubMed ID: 17256132 [TBL] [Abstract][Full Text] [Related]
39. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. Ben Reguiga M; Bonhomme-Faivre L; Farinotti R J Pharm Pharmacol; 2007 Mar; 59(3):401-8. PubMed ID: 17331344 [TBL] [Abstract][Full Text] [Related]
40. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Shin SC; Choi JS; Li X Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]